港股異動丨金斯瑞生物漲4.52% 細胞治療進展順利
格隆匯10月14日丨金斯瑞生物科技漲4.52%,報15.74港元,成交5728萬港元,總市值293億港元。

近日,“2019中國數字服務暨服務外包領軍企業”榜單正式揭曉。江蘇金斯瑞生物科技有限公司榮獲“醫藥健康行業領軍企業”及“百強企業”兩項稱號。廣發證券上個月發佈研報稱,細胞治療全球研發穩步推進,公司細胞治療產品中研發進度最為領先的BCMA CAR-T在中國和美國的二期臨牀均進展順利,入組均有望在2019年完成。2019年以來,該產品陸續獲得美國FDA孤兒藥認證和歐洲EMA優先藥物資格認定,標誌着中國原創創新藥真正走向歐美。2019年8月,公司已就該產品臨牀的進展獲得來自強生的第二和第三筆里程碑款。預計2019年12月的ASH會議將有更多關於該產品的臨牀數據發佈,未來更多的里程碑款也值得期待。廣發首次覆蓋給予“買入”評級, 目標價26.12 港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.